2012 revenue: $16.5 billion (est. May 2012-April 2013)
2011 revenue: $16.1 billion

Year in review: Simply put, it's been a nice, healthy stretch for Medtronic ($MDT). CEO Omar Ishrak has pushed hard to revamp Medtronic's business model to focus more on high-growth emerging markets such as India and China, and the company's fiscal 2013 third-quarter revenues (through Jan. 23, 2013) are an example of steady progress the company made in getting there through the entire year. While areas such as spinal devices and CRDM revenue continued to struggle, the company's emerging-markets revenue soared 20% during the quarter. In 2012, Medtronic also targeted acquisitions in China to propel its emerging-market growth, including its $816 million buyout of Chinese orthopedics outfit Kanghui Holdings and its $66.2 million investment in China's LifeTech Scientific, giving it a stake in the Chinese structural heart market. That strategy will continue well into 2013, Ishrak promised in early January during the J.P. Morgan Healthcare Conference in San Francisco.

For more:
Medtronic rides emerging markets growth to strong quarter
JPM: Medtronic's Ishrak promises more M&A, globalization